Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
Connie Kang, Yahiya Y. Syed
Drugs (2020) Vol. 80, Iss. 6, pp. 601-607
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
Uttpal Anand, Abhijit Dey, Arvind K. Singh Chandel, et al.
Genes & Diseases (2022) Vol. 10, Iss. 4, pp. 1367-1401
Open Access | Times Cited: 755
Current State of Breast Cancer Diagnosis, Treatment, and Theranostics
Arya Bhushan, Andrea Gonsalves, Jyothi U. Menon
Pharmaceutics (2021) Vol. 13, Iss. 5, pp. 723-723
Open Access | Times Cited: 176
Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome
Mercedes Tkach, Jessie Thalmensi, Eleonora Timperi, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 17
Open Access | Times Cited: 80
Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
Ying Li, Zhijun Zhan, Xuemin Yin, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 80
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Leisha A. Emens, Sylvia Adams, Ashley Cimino‐Mathews, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002597-e002597
Open Access | Times Cited: 68
Let-7a/cMyc/CCAT1/miR-17–5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1
Noha A. Selem, Heba Nafae, Tamer Manie, et al.
Pathology - Research and Practice (2023) Vol. 248, pp. 154579-154579
Closed Access | Times Cited: 26
Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
Tilahun Ayane Debele, Cheng-Fa Yeh, Wen‐Pin Su
Cancers (2020) Vol. 12, Iss. 12, pp. 3773-3773
Open Access | Times Cited: 59
Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression
Damiano Cosimo Rigiracciolo, Francesca Cirillo, Marianna Talia, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 645-645
Open Access | Times Cited: 42
Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple‐Negative Breast Cancer Treatment
Sofia Torres Quintas, Ana Manuela Canha Borges, Maria José Oliveira, et al.
Small (2023)
Open Access | Times Cited: 20
Immune-related biomarkers in triple-negative breast cancer
Juan Zhang, Qi Tian, Mi Zhang, et al.
Breast Cancer (2021) Vol. 28, Iss. 4, pp. 792-805
Open Access | Times Cited: 34
New therapy strategies in the management of breast cancer
Sevgi Yardım-Akaydın, Bensu Karahalıl, Sultan Nacak Baytaş
Drug Discovery Today (2022) Vol. 27, Iss. 6, pp. 1755-1762
Closed Access | Times Cited: 26
PD-L1 maintains neutrophil extracellular traps release by inhibiting neutrophil autophagy in endotoxin-induced lung injury
Cheng‐long Zhu, Jian Xie, Zhenzhen Zhao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Nanodrugs Targeting T Cells in Tumor Therapy
Maximilian Haist, Volker Mailänder, Matthias Bros
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 24
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach
Varduhi Petrosyan, Lacey E. Dobrolecki, Lillian R Thistlethwaite, et al.
iScience (2022) Vol. 26, Iss. 1, pp. 105799-105799
Open Access | Times Cited: 24
Biosynthesis of anticancer phytochemical compounds and their chemistry
Amandeep Dogra, Jitender Kumar
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 16
Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment
Mahsa Keihan Shokooh, Fakhrossadat Emami, Jee‐Heon Jeong, et al.
Pharmaceutics (2021) Vol. 13, Iss. 2, pp. 287-287
Open Access | Times Cited: 27
Combination of microtubule targeting agents with other antineoplastics for cancer treatment
Tingting Liang, Lu Lu, Xueting Song, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 5, pp. 188777-188777
Closed Access | Times Cited: 20
Impact of the Cancer Cell Secretome in Driving Breast Cancer Progression
Syazalina Zahari, Saiful Effendi Syafruddin, M. Aiman Mohtar
Cancers (2023) Vol. 15, Iss. 9, pp. 2653-2653
Open Access | Times Cited: 12
Serum Amyloid A1 Mediates Paclitaxel Resistance via MD2‐Dependent Pathways in Triple‐Negative Breast Cancer
Kangmin Chen, Yanni Zhao, Tianyang Jin, et al.
Drug Development Research (2025) Vol. 86, Iss. 2
Closed Access
Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer
Shaukat Ali, Mahnoor Arshad, Muhammad Summer, et al.
Journal of Oncology Pharmacy Practice (2025)
Closed Access
Photodynamic Biomimetic Liposomes Targeted to the Endoplasmic Reticulum Enhance Combined Immunotherapy for Triple-Negative Breast Cancer
Tianyang Li, Haimei Meng, Xinfeng Huang, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
Élia Cipriano, Alexandra Mesquita
Breast Cancer Basic and Clinical Research (2021) Vol. 15
Open Access | Times Cited: 24
Atezolizumab: A Review in Extensive-Stage SCLC
James E. Frampton
Drugs (2020) Vol. 80, Iss. 15, pp. 1587-1594
Closed Access | Times Cited: 25
Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
Yifan Ren, Jialong Song, Xinyi Li, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 8878-8878
Open Access | Times Cited: 15
Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses
Michael L. Monaco, Omer A. Idris, Karim Essani
Cancers (2023) Vol. 15, Iss. 8, pp. 2393-2393
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top